Pharmaceutical Investing FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
Pharmaceutical Investing FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL 9
